HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Judith V M G Bovée Selected Research

Chondroma (Enchondroma)

11/2020Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma.
1/2017IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas.
1/2009Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors.
9/2005cDNA expression profiling of chondrosarcomas: Ollier disease resembles solitary tumours and alteration in genes coding for components of energy metabolism occurs with increasing grade.
3/2005Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas.
3/2004Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Judith V M G Bovée Research Topics

Disease

58Neoplasms (Cancer)
10/2022 - 03/2004
40Chondrosarcoma
05/2021 - 03/2004
25Sarcoma (Soft Tissue Sarcoma)
01/2022 - 05/2013
17Osteosarcoma (Osteogenic Sarcoma)
01/2022 - 07/2015
9Neoplasm Metastasis (Metastasis)
11/2017 - 05/2009
7Myxoid Liposarcoma
01/2021 - 09/2010
7Leiomyosarcoma
01/2019 - 08/2013
6Glioma (Gliomas)
05/2021 - 01/2013
6Chondroma (Enchondroma)
11/2020 - 03/2004
4Carcinogenesis
09/2021 - 08/2013
4Hypoxia (Hypoxemia)
04/2019 - 04/2010
4Enchondromatosis (Ollier Disease)
06/2015 - 12/2004
3Cholangiocarcinoma
05/2021 - 10/2017
3Synovial Sarcoma (Synovioma)
02/2021 - 04/2015
3Pheochromocytoma
01/2021 - 11/2015
3Paraganglioma (Paragangliomas)
01/2021 - 11/2015
3Mesenchymal Chondrosarcoma
01/2019 - 03/2008
3Ewing Sarcoma (Sarcoma, Ewing)
10/2016 - 02/2010
3Fibroma (Fibromatosis)
12/2015 - 06/2005
2Osteoblastoma
01/2022 - 01/2017
2Bone Cysts (Bone Cyst)
12/2021 - 02/2010
2Wounds and Injuries (Trauma)
01/2021 - 01/2019
2Chondroblastoma
01/2020 - 09/2016
2Colorectal Neoplasms (Colorectal Cancer)
01/2020 - 08/2009
2Rhabdomyosarcoma
01/2020 - 01/2016
2Leukemia
12/2019 - 01/2013
2Margins of Excision
01/2019 - 01/2017
2Genomic Instability
01/2017 - 09/2016
2Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
09/2016 - 02/2010
2Liposarcoma
09/2016 - 01/2016
2Leiomyoma (Uterine Fibroids)
01/2016 - 08/2013
2Aggressive Fibromatosis (Desmoid)
12/2015 - 10/2013
2Smooth Muscle Tumor
11/2015 - 08/2013

Drug/Important Bio-Agent (IBA)

20Proteins (Proteins, Gene)FDA Link
01/2021 - 03/2004
12Biomarkers (Surrogate Marker)IBA
10/2022 - 04/2013
9DNA (Deoxyribonucleic Acid)IBA
12/2021 - 03/2007
9Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA
05/2021 - 01/2013
8Doxorubicin (Adriamycin)FDA LinkGeneric
01/2019 - 04/2013
7Phosphotransferases (Kinase)IBA
12/2019 - 08/2009
6RNA (Ribonucleic Acid)IBA
12/2021 - 01/2017
6Pharmaceutical PreparationsIBA
01/2021 - 01/2015
6Small Interfering RNA (siRNA)IBA
11/2020 - 09/2009
6CateninsIBA
01/2018 - 08/2013
5Transcription Factors (Transcription Factor)IBA
01/2022 - 02/2010
5alpha-hydroxyglutarateIBA
05/2021 - 01/2013
4Keratins (Keratin)IBA
01/2020 - 06/2010
4Histones (Histone)IBA
01/2020 - 01/2013
4ABT-737IBA
09/2018 - 04/2013
4Succinate Dehydrogenase (Fumarate Reductase)IBA
01/2018 - 11/2015
4isocitric acid (isocitrate)IBA
12/2017 - 01/2013
4ParaffinIBA
01/2017 - 05/2012
3NAD (NADH)IBA
06/2021 - 12/2017
3Chloroquine (Aralen)FDA LinkGeneric
05/2021 - 10/2017
3Metformin (Glucophage)FDA LinkGeneric
05/2021 - 10/2017
3Tyrosine Kinase InhibitorsIBA
01/2021 - 09/2010
3Fumarate Hydratase (Fumarase)IBA
01/2018 - 11/2015
3Formaldehyde (Formol)FDA Link
01/2017 - 12/2015
3ChromatinIBA
01/2017 - 01/2009
3Transforming Growth Factors (Transforming Growth Factor)IBA
01/2016 - 10/2012
3Messenger RNA (mRNA)IBA
11/2015 - 03/2009
3Plasminogen Activator Inhibitor 1IBA
09/2013 - 11/2009
3Cyclin D1IBA
09/2013 - 09/2009
2RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
12/2021 - 01/2018
2pazopanibFDA Link
11/2021 - 01/2018
2AntigensIBA
08/2021 - 04/2015
2Antimalarials (Antimalarial Agents)IBA
05/2021 - 10/2017
2Hypoglycemic Agents (Hypoglycemics)IBA
05/2021 - 10/2017
2Tricarboxylic AcidsIBA
01/2021 - 11/2015
2IfosfamideFDA LinkGeneric
01/2021 - 01/2020
2sapanisertibIBA
01/2020 - 04/2019
2Polysaccharides (Glycans)IBA
01/2020 - 01/2016
2Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
12/2019 - 01/2016
2SurvivinIBA
01/2019 - 08/2017
2Histone Deacetylase InhibitorsIBA
01/2019 - 10/2016
2Caspase 3 (Caspase-3)IBA
09/2018 - 09/2010
2Cisplatin (Platino)FDA LinkGeneric
09/2018 - 04/2013
2EnzymesIBA
01/2018 - 11/2015
2matrigelIBA
01/2018 - 01/2016
2CollagenIBA
12/2017 - 06/2012
2Imatinib Mesylate (Gleevec)FDA Link
11/2017 - 08/2009
25-hydroxymethylcytosineIBA
01/2017 - 11/2015
2histone H3 trimethyl Lys4IBA
01/2017 - 11/2015
2Biological ProductsIBA
01/2016 - 03/2005
2Insulin-Like PeptidesIBA
01/2016 - 07/2010
2Galectin 1 (LGALS1)IBA
01/2016 - 04/2010
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
11/2015 - 07/2013
2Codon (Codons)IBA
07/2014 - 10/2013
2Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
05/2014 - 07/2013
2Peptides (Polypeptides)IBA
04/2013 - 08/2009
2Transforming Growth Factor beta (TGF-beta)IBA
10/2012 - 11/2009
2Dasatinib (BMS 354825)FDA Link
09/2010 - 08/2009
2Matrix Metalloproteinases (MMPs)IBA
07/2010 - 04/2010

Therapy/Procedure

23Therapeutics
09/2021 - 03/2008
20Drug Therapy (Chemotherapy)
01/2021 - 08/2005
17Radiotherapy
01/2022 - 08/2005
5Immunotherapy
08/2021 - 04/2015
2Subcutaneous Injections
01/2022 - 03/2021
2Drug Tapering
01/2021 - 01/2018
2Lasers (Laser)
01/2020 - 07/2017
2Aftercare (After-Treatment)
12/2019 - 09/2010